The above disclosure is based on information available with the Company regarding status of the suppliers as defined under Section 2 of the Micro, Small and Medium Enterprises Development Act, 2006.
3.7 The management has certified the Fixed Assets installed and put to use & relied upon by the Auditors, being a technical matter. During the year, Borrowings cost capitalized up to March 31, 2024 is Nil (As at March 31, 2023 is Rs. Nil)
3.8 Previous year’s figures have been re-arranged and reclassified wherever necessary to make them comparable with the current year’s figures. The amounts have been rounded off to nearest lakh.
3.9 Approval of financial statements
The financial statements are approved by the Company’s Board of Directors and authorised for issue on 06th May 2024.
(iii) Corporate Social Responsibility (CSR)
As per Section 135 of the Companies Act, 2013, a company, meeting the applicability threshold, needs to spend at least 2% of its average net profit for the immediately preceding three financial years on corporate social responsibility (CSR) activities:
26 Segment Reporting
The Company is working under one business segment only i.e. Pharmceuticals. These pharmaceutical products are having different applications. Besides there is not any significant variances on geographical basis, so the segment reporting defined under Ind AS 108 is not applicable.
|